Fundraising Fox

/Companies

Huxley Medical

Atlanta, US · Founded 2019 · Delaware corporation · 2 known investors

Find your way into Huxley Medical

Sign up to see every warm intro you have to Huxley Medical

Paths you didn't know you had: your email and LinkedIn already hold routes to the Huxley Medical team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with Google Already have an account? Log in

Huxley develops SANSA, a cellular-enabled chest-worn monitor and diagnostic service that detects obstructive and central sleep apnea and records ECG from a single at-home device. It serves sleep labs, cardiology clinics, and primary care providers with AI-assisted reporting and managed testing logistics.

AI & Machine Learning Digital Health Healthtech Medical Devices

Founders & leadership

CH

Christopher Hallett

Christopher Hallett Chief Commercial Officer (CCO)2023–2025Christopher Hallett held the role of Chief Commercial Officer at Huxley Medical, where he co-founded and helped scale the SANSA dual-diagnostic device through commercialization and fundraising. Prior to Huxley, he built commercial teams at CardioFocus, Boston Scientific, Itamar Medical, and Biosense Webster, with expertise spanning electrophysiology, diagnostics, and sleep monitoring.

CL

Christopher LeeExecutive

DB

Daniel Burnham

Daniel Burnham Chief Technology OfficerDaniel Burnham is Chief Technology Officer and advisor at Huxley Medical, which develops cellular-enabled wearable diagnostic devices for sleep and cardiac monitoring. He brings over a decade of experience in medical device product development, regulatory strategy, and engineering, with expertise in FDA approval processes and relevant standards including 62304, 60601, and 14971.

BT

Brennan Torstrick

Brennan TorstrickPresident of Product & Market Strategy, Co-founder

KG

Kenneth GallNamed on SEC filing

Board

KJ

Kurt JacobusBoard directorSenior Advisor at GRA Venture

MP

Michael Porter

Michael Porter Board Member & Investor

WC

William CoxBoard director

DB

Drew BeaverBoard director

Investors · 2

Duke Capital Partnerslisted by Duke Capital PartnersDurham

GRA Venturelisted by GRA VentureGeorgia

How we know: GRA Venture's portfolio page · funding news · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$50.7M disclosed across 10 rounds · 2021–2026

▶$11MraisedSep 2026 · 40 investors · Other Health Care

Rule 506(b)

Officers, directors & promoters on the filing

Christopher LeeExecutive Officer, Director
Brennan TorstrickExecutive Officer, Director
Kenneth GallDirector
Kurt JacobusDirector
Michael PorterDirector
William CoxDirector
Drew BeaverDirector

Offering amount: $11.7M
Amount sold: $11M
Minimum investment: $1.2K
First sale: Sep 2026
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$3MraisedJun 2026 · 20 investors · Other Health Care

Rule 506(b)

Officers, directors & promoters on the filing

William CoxDirector
Brennan TorstrickExecutive Officer, Director
Kurt JacobusDirector
Kenneth GallDirector
Daniel BurnhamExecutive Officer
Christopher LeeExecutive Officer, Director

Offering amount: $3M
Amount sold: $3M
Minimum investment: $1.7K
First sale: Apr 2026
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$10MraisedFeb 2026 · 58 investors · Other Health Care

Rule 506(b)

Officers, directors & promoters on the filing

Daniel BurnhamExecutive Officer
Michael PorterDirector
William CoxDirector
Brennan TorstrickExecutive Officer, Director
Kenneth GallDirector
Christopher LeeExecutive Officer, Director

Offering amount: $10M
Amount sold: $10M
Minimum investment: $5K
First sale: Nov 2025
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$1.7MraisedSep 2025 · 16 investors · Other Health Care

Rule 506(b)

Officers, directors & promoters on the filing

Christopher LeeExecutive Officer, Director
Daniel BurnhamExecutive Officer
Kurt JacobusDirector
Michael PorterDirector
William CoxDirector
Kenneth GallDirector
Brennan TorstrickExecutive Officer, Director

Offering amount: $2M
Amount sold: $1.7M
Minimum investment: $25K
First sale: May 2025
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$4.6MraisedDec 2024 · 60 investors · Other Health Care

Rule 506(b)

Officers, directors & promoters on the filing

Brennan TorstrickExecutive Officer, Director
Kurt JacobusDirector
Christopher HallettExecutive Officer, Director
Christopher LeeExecutive Officer, Director
Michael PorterDirector
William CoxDirector
Daniel BurnhamExecutive Officer
Kenneth GallDirector

Offering amount: $8M
Amount sold: $4.6M
Minimum investment: $2K
First sale: Nov 2024
Incorporated: Corporation, Delaware, 2019
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$5.4MraisedApr 2024 · 105 investors · Other Health Care

Rule 506(b)

Officers, directors & promoters on the filing

Michael PorterDirector
William CoxDirector
Christopher HallettExecutive Officer, Director
Brennan TorstrickExecutive Officer, Director
Christopher LeeExecutive Officer, Director

Offering amount: $6M
Amount sold: $5.4M
First sale: Feb 2024
Incorporated: Corporation, Delaware, 2019
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$7.2MraisedJun 2023 · 85 investors · Other Health Care

Rule 506(b)

Officers, directors & promoters on the filing

Chris LeeExecutive Officer, Promoter
Brennan TorstrickExecutive Officer

Offering amount: $8.1M
Amount sold: $7.2M
Minimum investment: $100K
First sale: May 2023
Incorporated: Corporation, Delaware, 2019
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$2.9MraisedApr 2023 · 52 investors · Other Health Care

Rule 506(b)

Officers, directors & promoters on the filing

Brennan TorstrickExecutive Officer
Chris LeeExecutive Officer, Promoter

Offering amount: $3M
Amount sold: $2.9M
Minimum investment: $2.4K
First sale: Jun 2022
Incorporated: Corporation, Delaware, 2019
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 2

HellosunriseSunrise develops a wireless single-use sensor and companion iOS/Android app that records the respiratory signal at its source to detect sleep apnea at home in one night. It provides clinical reports that patients can share with their doctor or the company's network of partner sleep specialists for diagnosis and tailored treatment.

MedBridge HealthcareMedBridge operates sleep disorder diagnostic centers and provides integrated sleep laboratory management services to hospitals and healthcare systems. The company combines clinical services with a software platform to manage patient care for sleep disorder diagnosis and treatment.

Companies working in the same space as Huxley Medical.

In the news

Huxley Medical Shares New Data at SLEEP Demonstrating Breadth of Clinical Insights Enabled by SANSA Diagnostic Platformprnewswire.com · Jun 2025

Huxley Medical Announces FDA Clearance for Cellular-Enabled SANSA Home Sleep Apnea Testprnewswire.com · Feb 2025

Frequently asked questions

What does Huxley Medical do?: Huxley develops SANSA, a cellular-enabled chest-worn monitor and diagnostic service that detects obstructive and central sleep apnea and records ECG from a single at-home device. It serves sleep labs, cardiology clinics, and primary care providers with AI-assisted reporting and managed testing logistics.
Who are Huxley Medical's investors?: Huxley Medical's investors include Duke Capital Partners, GRA Venture.
How much funding has Huxley Medical raised?: Huxley Medical has disclosed $50.7M raised across 10 rounds.
Where is Huxley Medical headquartered?: Huxley Medical is headquartered in Atlanta, US.